BioVie Inc. BIVI

Company Overview

BioVie Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for neurological and neurodegenerative disorders, as well as conditions involving chronic inflammation and metabolic dysfunction. The company operates within the biopharmaceutical industry and primarily generates value through the research, development, and commercialization potential of proprietary drug candidates rather than through commercial product sales. Its development programs have centered on treatments for diseases with significant unmet medical need, including Parkinson’s disease and Alzheimer’s disease.

The company’s primary assets include bezisterim (NE3107), an investigational small-molecule therapy designed to modulate inflammatory and insulin-signaling pathways associated with neurodegenerative disease. BioVie has also previously advanced liver disease-related therapeutic programs, including ascites-related treatments, reflecting its historical focus on inflammation-driven conditions. BioVie traces its origins to a biotechnology platform focused on chronic liver disease before expanding into neurology-oriented development programs through licensing and acquisition activity intended to reposition the company toward larger commercial markets.